1. Kuhar, M. J. 1993. Neurotransmitter transporters as drug targets: recent research with a focus on the dopamine transporter. Pharmacologist, 35:28–33.
2. Devine, D. P., Leone, P., Pockok, D., and Wise, R. A. 1993. Differential involvement of ventral tegmental mu. delta and kappa receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266:1236–1246.
3. Spanagel, R., Herz, A., and Shippenberg, T. S. 1992. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 89:2046–2050.
4. Jiang, Q., Seyed-Mozaffari, A., Archer, S., and Bidlack, J. M. 1992. Characterization of antinociceptive actions of alkylating derivatives of morphinone: 14β-(thioglycolamido)-7,8-dihydro-morphinone (TAMO) and 14β(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J. Pharmacol. Exp. Ther. 262, 526–531.
5. Archer, S., Seyed-Mozaffari, A., Jiang, Q., and Bidlack, J. M. 1994. 14α-14β [Dithiobis(2-oxo-2, 1-ethanediyl)imino]]bis-7,8-dihydromorphinone and 14α-14β-[dithiobis-92-oxo-2,1-ethanediyl)imino]]bis-7,8-dihydro-(cyclopropylmethyl)-normorphine. Chemistry and opioid binding properties. J. Med. Chem. 37, 1578–1585.